Previous close | 1.5000 |
Open | 1.5000 |
Bid | 0.7000 |
Ask | 3.5000 |
Strike | 35.00 |
Expiry date | 2024-08-16 |
Day's range | 1.5000 - 1.5000 |
Contract range | N/A |
Volume | |
Open interest | 23 |
Unlock your portfolio value by investing in stocks like HRMY, GPRK, GCT, CMRE and ARKO to fetch handsome returns.
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that the U.S. Food and Drug Administration denied the Citizen Petition filed by a short seller claiming that WAKIX is not safe and effective for the treatment of excessive daytime sleepiness (EDS) and cataplexy in adults with narcolepsy. The Agency's decision to reject the Petition was anticipated and confirms the Company's long-held position that the allegations in the Petition were unfounded and without merit.
Harmony Biosciences (Nasdaq: HRMY) today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for WAKIX® (pitolisant) tablets for the treatment of excessive daytime sleepiness (EDS) in pediatric patients 6 years of age and older with narcolepsy. The FDA separated the submission into two sNDAs for administrative purposes to issue an approval for the treatment of EDS and a complete response for the treatment of cataplexy in pediatric